Global Myasthenia Gravis Disease Treatment Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2024

  • receipt Report ID : 161184
  • calendar_today Published On: Apr, 2019
  • file_copy Pages: 123
  • list Pharmaceuticals and Healthcare

Myasthenia gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body. This condition occurs due to the impairment of communication between muscles and nerve cells. This impairment causes difficulties in the contraction and relaxation of muscles which are crucial for carrying out daily activities, resulting in muscle weakness. It mostly affects the muscles that control the eyes and eyelids, facial expressions, chewing, and speaking.

Scope of the Report:

The Americas accounted for the largest market share of the global myasthenia gravis disease market owing to the growing number of drug manufacturers, increasing awareness about the long-term effects of muscle dystrophy, and rising government funding for the treatment of this disease in the region. Moreover, the U.S. contributes to a significant market share in the global pharmaceutical industry.

The global Myasthenia Gravis Disease Treatment market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Myasthenia Gravis Disease Treatment.

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

This report studies the Myasthenia Gravis Disease Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Myasthenia Gravis Disease Treatment market by product type and applications/end industries.

Market Segment by Companies, this report covers

GlaxoSmithKline

Novartis

Teva Pharmaceutical

Roche

Bristol-Myers Squibb

Apotex

Cipla

Biogen

AbbVie

Valeant Pharmaceuticals

Sun Pharmaceuticals

Fresenius Kabi

Piramal Healthcare

RPG Life Sciences

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Medication

Surgery

Others

Market Segment by Applications, can be divided into

Hospitals

Clinics

Others

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Myasthenia Gravis Disease Treatment Market Overview

1.1 Product Overview and Scope of Myasthenia Gravis Disease Treatment

1.2 Classification of Myasthenia Gravis Disease Treatment by Types

1.2.1 Global Myasthenia Gravis Disease Treatment Revenue Comparison by Types (2017-2023)

1.2.2 Global Myasthenia Gravis Disease Treatment Revenue Market Share by Types in 2017

1.2.3 Medication

1.2.4 Surgery

1.2.5 Others

1.3 Global Myasthenia Gravis Disease Treatment Market by Application

1.3.1 Global Myasthenia Gravis Disease Treatment Market Size and Market Share Comparison by Applications (2013-2023)

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Others

1.4 Global Myasthenia Gravis Disease Treatment Market by Regions

1.4.1 Global Myasthenia Gravis Disease Treatment Market Size (Million USD) Comparison by Regions (2013-2023)

1.4.1 North America (USA, Canada and Mexico) Myasthenia Gravis Disease Treatment Status and Prospect (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy) Myasthenia Gravis Disease Treatment Status and Prospect (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Myasthenia Gravis Disease Treatment Status and Prospect (2013-2023)

1.4.4 South America (Brazil, Argentina, Colombia) Myasthenia Gravis Disease Treatment Status and Prospect (2013-2023)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Myasthenia Gravis Disease Treatment Status and Prospect (2013-2023)

1.5 Global Market Size of Myasthenia Gravis Disease Treatment (2013-2023)

2 Manufacturers Profiles

2.1 GlaxoSmithKline

2.1.1 Business Overview

2.1.2 Myasthenia Gravis Disease Treatment Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 GlaxoSmithKline Myasthenia Gravis Disease Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.2 Novartis

2.2.1 Business Overview

2.2.2 Myasthenia Gravis Disease Treatment Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Novartis Myasthenia Gravis Disease Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.3 Teva Pharmaceutical

2.3.1 Business Overview

2.3.2 Myasthenia Gravis Disease Treatment Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Teva Pharmaceutical Myasthenia Gravis Disease Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.4 Roche

2.4.1 Business Overview

2.4.2 Myasthenia Gravis Disease Treatment Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Roche Myasthenia Gravis Disease Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.5 Bristol-Myers Squibb

2.5.1 Business Overview

2.5.2 Myasthenia Gravis Disease Treatment Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Bristol-Myers Squibb Myasthenia Gravis Disease Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.6 Apotex

2.6.1 Business Overview

2.6.2 Myasthenia Gravis Disease Treatment Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Apotex Myasthenia Gravis Disease Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.7 Cipla

2.7.1 Business Overview

2.7.2 Myasthenia Gravis Disease Treatment Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Cipla Myasthenia Gravis Disease Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.8 Biogen

2.8.1 Business Overview

2.8.2 Myasthenia Gravis Disease Treatment Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 Biogen Myasthenia Gravis Disease Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.9 AbbVie

2.9.1 Business Overview

2.9.2 Myasthenia Gravis Disease Treatment Type and Applications

2.9.2.1 Product A

2.9.2.2 Product B

2.9.3 AbbVie Myasthenia Gravis Disease Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.10 Valeant Pharmaceuticals

2.10.1 Business Overview

2.10.2 Myasthenia Gravis Disease Treatment Type and Applications

2.10.2.1 Product A

2.10.2.2 Product B

2.10.3 Valeant Pharmaceuticals Myasthenia Gravis Disease Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.11 Sun Pharmaceuticals

2.11.1 Business Overview

2.11.2 Myasthenia Gravis Disease Treatment Type and Applications

2.11.2.1 Product A

2.11.2.2 Product B

2.11.3 Sun Pharmaceuticals Myasthenia Gravis Disease Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.12 Fresenius Kabi

2.12.1 Business Overview

2.12.2 Myasthenia Gravis Disease Treatment Type and Applications

2.12.2.1 Product A

2.12.2.2 Product B

2.12.3 Fresenius Kabi Myasthenia Gravis Disease Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.13 Piramal Healthcare

2.13.1 Business Overview

2.13.2 Myasthenia Gravis Disease Treatment Type and Applications

2.13.2.1 Product A

2.13.2.2 Product B

2.13.3 Piramal Healthcare Myasthenia Gravis Disease Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.14 RPG Life Sciences

2.14.1 Business Overview

2.14.2 Myasthenia Gravis Disease Treatment Type and Applications

2.14.2.1 Product A

2.14.2.2 Product B

2.14.3 RPG Life Sciences Myasthenia Gravis Disease Treatment Revenue, Gross Margin and Market Share (2016-2017)

3 Global Myasthenia Gravis Disease Treatment Market Competition, by Players

3.1 Global Myasthenia Gravis Disease Treatment Revenue and Share by Players (2013-2018)

3.2 Market Concentration Rate

3.2.1 Top 5 Myasthenia Gravis Disease Treatment Players Market Share

3.2.2 Top 10 Myasthenia Gravis Disease Treatment Players Market Share

3.3 Market Competition Trend

4 Global Myasthenia Gravis Disease Treatment Market Size by Regions

4.1 Global Myasthenia Gravis Disease Treatment Revenue and Market Share by Regions

4.2 North America Myasthenia Gravis Disease Treatment Revenue and Growth Rate (2013-2018)

4.3 Europe Myasthenia Gravis Disease Treatment Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific Myasthenia Gravis Disease Treatment Revenue and Growth Rate (2013-2018)

4.5 South America Myasthenia Gravis Disease Treatment Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa Myasthenia Gravis Disease Treatment Revenue and Growth Rate (2013-2018)

5 North America Myasthenia Gravis Disease Treatment Revenue by Countries

5.1 North America Myasthenia Gravis Disease Treatment Revenue by Countries (2013-2018)

5.2 USA Myasthenia Gravis Disease Treatment Revenue and Growth Rate (2013-2018)

5.3 Canada Myasthenia Gravis Disease Treatment Revenue and Growth Rate (2013-2018)

5.4 Mexico Myasthenia Gravis Disease Treatment Revenue and Growth Rate (2013-2018)

6 Europe Myasthenia Gravis Disease Treatment Revenue by Countries

6.1 Europe Myasthenia Gravis Disease Treatment Revenue by Countries (2013-2018)

6.2 Germany Myasthenia Gravis Disease Treatment Revenue and Growth Rate (2013-2018)

6.3 UK Myasthenia Gravis Disease Treatment Revenue and Growth Rate (2013-2018)

6.4 France Myasthenia Gravis Disease Treatment Revenue and Growth Rate (2013-2018)

6.5 Russia Myasthenia Gravis Disease Treatment Revenue and Growth Rate (2013-2018)

6.6 Italy Myasthenia Gravis Disease Treatment Revenue and Growth Rate (2013-2018)

7 Asia-Pacific Myasthenia Gravis Disease Treatment Revenue by Countries

7.1 Asia-Pacific Myasthenia Gravis Disease Treatment Revenue by Countries (2013-2018)

7.2 China Myasthenia Gravis Disease Treatment Revenue and Growth Rate (2013-2018)

7.3 Japan Myasthenia Gravis Disease Treatment Revenue and Growth Rate (2013-2018)

7.4 Korea Myasthenia Gravis Disease Treatment Revenue and Growth Rate (2013-2018)

7.5 India Myasthenia Gravis Disease Treatment Revenue and Growth Rate (2013-2018)

7.6 Southeast Asia Myasthenia Gravis Disease Treatment Revenue and Growth Rate (2013-2018)

8 South America Myasthenia Gravis Disease Treatment Revenue by Countries

8.1 South America Myasthenia Gravis Disease Treatment Revenue by Countries (2013-2018)

8.2 Brazil Myasthenia Gravis Disease Treatment Revenue and Growth Rate (2013-2018)

8.3 Argentina Myasthenia Gravis Disease Treatment Revenue and Growth Rate (2013-2018)

8.4 Colombia Myasthenia Gravis Disease Treatment Revenue and Growth Rate (2013-2018)

9 Middle East and Africa Revenue Myasthenia Gravis Disease Treatment by Countries

9.1 Middle East and Africa Myasthenia Gravis Disease Treatment Revenue by Countries (2013-2018)

9.2 Saudi Arabia Myasthenia Gravis Disease Treatment Revenue and Growth Rate (2013-2018)

9.3 UAE Myasthenia Gravis Disease Treatment Revenue and Growth Rate (2013-2018)

9.4 Egypt Myasthenia Gravis Disease Treatment Revenue and Growth Rate (2013-2018)

9.5 Nigeria Myasthenia Gravis Disease Treatment Revenue and Growth Rate (2013-2018)

9.6 South Africa Myasthenia Gravis Disease Treatment Revenue and Growth Rate (2013-2018)

10 Global Myasthenia Gravis Disease Treatment Market Segment by Type

10.1 Global Myasthenia Gravis Disease Treatment Revenue and Market Share by Type (2013-2018)

10.2 Global Myasthenia Gravis Disease Treatment Market Forecast by Type (2018-2023)

10.3 Medication Revenue Growth Rate (2013-2023)

10.4 Surgery Revenue Growth Rate (2013-2023)

10.5 Others Revenue Growth Rate (2013-2023)

11 Global Myasthenia Gravis Disease Treatment Market Segment by Application

11.1 Global Myasthenia Gravis Disease Treatment Revenue Market Share by Application (2013-2018)

11.2 Myasthenia Gravis Disease Treatment Market Forecast by Application (2018-2023)

11.3 Hospitals Revenue Growth (2013-2018)

11.4 Clinics Revenue Growth (2013-2018)

11.5 Others Revenue Growth (2013-2018)

12 Global Myasthenia Gravis Disease Treatment Market Size Forecast (2018-2023)

12.1 Global Myasthenia Gravis Disease Treatment Market Size Forecast (2018-2023)

12.2 Global Myasthenia Gravis Disease Treatment Market Forecast by Regions (2018-2023)

12.3 North America Myasthenia Gravis Disease Treatment Revenue Market Forecast (2018-2023)

12.4 Europe Myasthenia Gravis Disease Treatment Revenue Market Forecast (2018-2023)

12.5 Asia-Pacific Myasthenia Gravis Disease Treatment Revenue Market Forecast (2018-2023)

12.6 South America Myasthenia Gravis Disease Treatment Revenue Market Forecast (2018-2023)

12.7 Middle East and Africa Myasthenia Gravis Disease Treatment Revenue Market Forecast (2018-2023)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source

List of Tables and Figures

Figure Myasthenia Gravis Disease Treatment Picture

Table Product Specifications of Myasthenia Gravis Disease Treatment

Table Global Myasthenia Gravis Disease Treatment and

Please fill the form below, to recieve the report sample


+1